Literature DB >> 27249692

The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Thomas E Hutson1, Gregory R Thoreson1, Robert A Figlin1, Brian I Rini1.   

Abstract

The treatment landscape for renal cell carcinoma (RCC) is a dynamic process that has seen considerable change in recent years. We have seen a rebirth of original breakthroughs with immune checkpoint inhibitors showing promise in patients with treatment-refractory disease. The optimal sequencing of treatments and incorporation of novel therapeutics are actively being investigated and have yet to be determined. The clinical challenges of this evolving treatment paradigm can be attributed to cost considerations, toxicity, and defining endpoints in the management of advanced RCC. As novel therapeutics emerge, finding the optimal treatment regimen for patients will have an increasing focus on patient-centered outcomes and improvement in quality of life in addition to improving survival.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27249692     DOI： 10.1200/EDBK_158892

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN： 1548-8748


  7 in total

Review 1.  Targeted therapies for renal cell carcinoma.

Authors:  Edwin M Posadas; Suwicha Limvorasak; Robert A Figlin
Journal:  Nat Rev Nephrol       Date:  2017-07-10       Impact factor: 28.314

2.  Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma.

Authors:  R Crocchiolo; O Ringden; J-O Bay; D Blaise; B Omasic; B Mazzi; C Picard; S Trinca; L Barkholt; J Peccatori; S Gregori; G Amodio; K Fleischhauer; F Ciceri; M Bregni
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

Review 3.  Imaging for Metastatic Renal Cell Carcinoma.

Authors:  Soumya V L Vig; Elcin Zan; Stella K Kang
Journal:  Urol Clin North Am       Date:  2020-06-11       Impact factor: 2.241

4.  Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).

Authors:  Roberto Pili; David I Quinn; Hans J Hammers; Paul Monk; Saby George; Tanya B Dorff; Thomas Olencki; Li Shen; Ashley Orillion; Dominick Lamonica; Roberto S Fragomeni; Zsolt Szabo; Alan Hutson; Adrienne Groman; Susan M Perkins; Richard Piekarz; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2017-09-22       Impact factor: 12.531

Review 5.  Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.

Authors:  Alexandre Ingels; Riccardo Campi; Umberto Capitanio; Daniele Amparore; Riccardo Bertolo; Umberto Carbonara; Selcuk Erdem; Önder Kara; Tobias Klatte; Maximilian C Kriegmair; Michele Marchioni; Maria C Mir; Idir Ouzaïd; Nicola Pavan; Angela Pecoraro; Eduard Roussel; Alexandre de la Taille
Journal:  Nat Rev Urol       Date:  2022-05-11       Impact factor: 16.430

6.  Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model.

Authors:  Dongrul Shin; Chang Wook Jeong; Cheryn Song; Minyong Kang; Seong Il Seo; Jung Kwon Kim; Hakmin Lee; Jinsoo Chung; Sung-Hoo Hong; Eu Chang Hwang; Cheol Kwak; Jae Young Park
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

7.  Efficacy of Neoadjuvant Targeted Therapy in Treatment of Patients with Localised Clear-Cell Renal Cell Carcinoma.

Authors:  O A Voylenko; O E Stakhovsky; I V Vitruk; O A Kononenko; M V Pikul; S L Semko; E O Stakhovsky
Journal:  Adv Urol       Date:  2021-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.